Literature DB >> 12933609

Clustered encouragement designs with individual noncompliance: bayesian inference with randomization, and application to advance directive forms.

Constantine E Frangakis1, Donald B Rubin, Xiao-Hua Zhou.   

Abstract

In many studies comparing a new 'target treatment' with a control target treatment, the received treatment does not always agree with assigned treatment-that is, the compliance is imperfect. An obvious example arises when ethical or practical constraints prevent even the randomized assignment of receipt of the new target treatment but allow the randomized assignment of the encouragement to receive this treatment. In fact, many randomized experiments where compliance is not enforced by the experimenter (e.g. with non-blinded assignment) may be more accurately thought of as randomized encouragement designs. Moreover, often the assignment of encouragement is at the level of clusters (e.g. doctors) where the compliance with the assignment varies across the units (e.g. patients) within clusters. We refer to such studies as 'clustered encouragement designs' (CEDs) and they arise relatively frequently (e.g. Sommer and Zeger, 1991; McDonald et al., 1992; Dexter et al., 1998) Here, we propose Bayesian methodology for causal inference for the effect of the new target treatment versus the control target treatment in the randomized CED with all-or-none compliance at the unit level, which generalizes the approach of Hirano et al. (2000) in important and surprisingly subtle ways, to account for the clustering, which is necessary for statistical validity. We illustrate our methods using data from a recent study exploring the role of physician consulting in increasing patients' completion of Advance Directive forms.

Entities:  

Year:  2002        PMID: 12933609     DOI: 10.1093/biostatistics/3.2.147

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  17 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Pitfalls of and controversies in cluster randomization trials.

Authors:  Allan Donner; Neil Klar
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

3.  THE POTENTIAL FOR BIAS IN PRINCIPAL CAUSAL EFFECT ESTIMATION WHEN TREATMENT RECEIVED DEPENDS ON A KEY COVARIATE.

Authors:  Corwin M Zigler; Thomas R Belin
Journal:  Ann Appl Stat       Date:  2011       Impact factor: 2.083

4.  Cluster randomized trials with treatment noncompliance.

Authors:  Booil Jo; Tihomir Asparouhov; Bengt O Muthén; Nicholas S Ialongo; C Hendricks Brown
Journal:  Psychol Methods       Date:  2008-03

5.  Causal Mediation Analyses for Randomized Trials.

Authors:  Kevin G Lynch; Mark Cary; Robert Gallop; Thomas R Ten Have
Journal:  Health Serv Outcomes Res Methodol       Date:  2008

6.  Using latent outcome trajectory classes in causal inference.

Authors:  Booil Jo; Chen-Pin Wang; Nicholas S Ialongo
Journal:  Stat Interface       Date:  2009-01-01       Impact factor: 0.582

7.  Person mobility in the design and analysis of cluster-randomized cohort prevention trials.

Authors:  Sam Vuchinich; Brian R Flay; Lawrence Aber; Leonard Bickman
Journal:  Prev Sci       Date:  2012-06

8.  Identification and Estimation of Causal Mechanisms in Clustered Encouragement Designs: Disentangling Bed Nets using Bayesian Principal Stratification.

Authors:  Laura Forastiere; Fabrizia Mealli; Tyler J VanderWeele
Journal:  J Am Stat Assoc       Date:  2016-08-18       Impact factor: 5.033

Review 9.  Adaptive designs for randomized trials in public health.

Authors:  C Hendricks Brown; Thomas R Ten Have; Booil Jo; Getachew Dagne; Peter A Wyman; Bengt Muthén; Robert D Gibbons
Journal:  Annu Rev Public Health       Date:  2009       Impact factor: 21.981

10.  Intention-to-treat analysis in cluster randomized trials with noncompliance.

Authors:  Booil Jo; Tihomir Asparouhov; Bengt O Muthén
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.